Study of cedar pollen-specific s-IgA in pollinosis patients and healthy subjects

Study of cedar pollen-specific s-IgA in pollinosis patients and healthy subjects - Study of cedar pollen-specific s-IgA in pollinosis patients and healthy subjects

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000054636

Enrollment

Registered

2024-06-12

Start date

2024-06-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pollinosis patients and subjects without allergic disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Males and females from 20 to 64 years of age (2) Subjects receiving a sufficient briefing of the objective and content of the present study, fully understanding and agreeing to voluntarily participate in the study and being able to personally sign a written informed consent (3) Subjects who meet any of the following criteria a) Subjects with hay fever symptoms during the pollen dispersal period, positive for specific IgE (cedar) (class 2 or higher), and diagnosed as having moderate or higher hay fever by a physician b) Subjects who have no reported allergic disease and whose specific IgE (cedar) is less than false positive (class 1) and whose nonspecific IgE antibodies are less than or equal to the reference value

Exclusion criteria

Exclusion criteria: (1) Subjects who used steroid medication within 4 weeks prior to the test (2) Subjects who have difficulty restricting the use of medications that may affect nasal or eye discomfort for one month prior to the test (3) Subjects with bronchial asthma (4) Subjects who have received specific or non-specific immunotherapy in the past (5) Subjects who have problems or diseases involving bleeding in the oral cavity or who are undergoing dental treatment (6) Subjects who are judged to be unsuitable as subjects based on the answers to the background survey (7) Subjects who are judged as unsuitable for the study based on the results of the test (8) Subjects who are judged as unsuitable for the study by the principal investigator or the investigator for other reason

Design outcomes

Primary

Measure	Time frame
Specific IgE antibody (cedar), nonspecific IgE antibody, SBP-specific IgG4, SBP-specific IgA, salivary secretory IgA (Total, SBP-specific)	—

Countries

Japan

Contacts

Public ContactHiroyasu Shimada

EP Mediate Co., Ltd. Foods Department Trial Planning Section

shimada.hiroyasu767@eps.co.jp090-5219-2774

Outcome results